AstraZeneca’s late-stage Tezspire study showed better tissue healing and swallowing relief than placebo, with benefits lasting through week 52. Common side effects matched approved uses, but the report does not say Tezspire is approved for this disease.
These results strengthen the case for Tezspire as a possible treatment for another disease. Both doses improved tissue healing and swallowing compared with placebo, and the benefits lasted through week 52. The report says common side effects matched the drug’s approved uses, but it does not report approval for this disease.
Amgen’s shared Tezspire study showed much higher tissue healing than placebo, with benefits lasting through week 52. Common side effects matched approved uses, but the report does not say Tezspire is approved for this disease.
Follow AstraZeneca Plc (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN